Sleep medications do not have one shared list of side effects. Prescription hypnotics, sedating antidepressants, over-the-counter antihistamines, melatonin products, and herbal supplements work differently. A risk that is central to one drug, such as dangerous withdrawal from a benzodiazepine, should not be transferred to every product sold for sleep.
The exact generic name matters more than the phrase “sleep aid.” So do the formulation, why it is being used, other medicines and substances, age, pregnancy, liver or kidney function, breathing health, and history of falls or unusual nighttime behavior.
Next-day sleepiness, dizziness, slower reactions, or poor coordination appear across several medication groups, but not at the same frequency or intensity 123. Some products have additional risks involving memory, complex sleep behavior, breathing, mood, tolerance, physical dependence, or withdrawal. The sections below explain which concerns belong to which medication groups and what deserves prompt attention.
First identify what you are taking
A brand name may not reveal the active ingredient. Some nighttime cold, allergy, and pain products contain the same sedating antihistamine as an over-the-counter sleep aid 3. Prescription drugs used for sleep may also have been developed for another condition.
| Medication group | Examples | Side effects and safety concerns that stand out |
|---|---|---|
| Benzodiazepines used as hypnotics | Temazepam, triazolam, estazolam | Sleepiness, slowed reactions, impaired coordination and memory, falls, and additive breathing suppression with opioids, alcohol, or other central nervous system depressants. FDA boxed warnings cover misuse, addiction, physical dependence, and potentially dangerous withdrawal 456. |
| Nonbenzodiazepine hypnotics, often called Z-drugs | Eszopiclone, zaleplon, zolpidem | Next-day impairment, dizziness, amnesia, and falls. FDA requires a boxed warning about rare complex sleep behaviors that have caused serious injury or death 716. |
| Dual orexin receptor antagonists | Daridorexant, lemborexant, suvorexant | Sleepiness, fatigue, headache, next-day impairment, sleep paralysis, sleep-related hallucinations, and occasionally complex sleep behavior. Exact respiratory, mood, interaction, and impairment warnings differ by product; daridorexant is one representative label 2. |
| Melatonin-receptor agonist | Ramelteon | Sleepiness, dizziness, fatigue, and nausea. Its label also describes rare severe allergic reactions and reports of abnormal thinking or behavior. Ramelteon is not a benzodiazepine, and a benzodiazepine withdrawal profile should not be assigned to it 8. |
| Low-dose doxepin formulated for insomnia | Doxepin sold for sleep-maintenance insomnia | Sleepiness or sedation and nausea are common label-listed effects. Alcohol and other sedating drugs may intensify impairment. The insomnia formulation should not be treated as equivalent to every antidepressant dose or formulation of doxepin 9. |
| Other sedating antidepressants or antipsychotics used off-label | Trazodone, mirtazapine, amitriptyline, quetiapine | These medicines do not form one pharmacologic class, so their adverse effects need to be checked individually. “Off-label” means the specific insomnia use is not FDA approved, not that every use is inappropriate. Current VA/DoD guidance suggests against trazodone and antipsychotics for chronic insomnia 10. |
| First-generation antihistamines sold for sleep | Diphenhydramine, doxylamine | Drowsiness, impaired driving, dry mouth, constipation, blurred vision, confusion, and difficulty urinating. Tolerance to the sedating effect can develop, and duplicate ingredients across combination products can lead to accidental overdose 36. |
| Melatonin and other dietary supplements | Melatonin, valerian, 5-HTP, kava | Effects depend on the ingredient. Melatonin may cause headache, dizziness, nausea, or sleepiness, and the amount in a supplement may differ from its label. Long-term safety data are limited. Valerian, 5-HTP, and kava have different interaction and safety concerns and should not be treated as interchangeable with melatonin 1112. |
This table is an orientation, not a substitute for the label attached to a particular prescription or product. A pharmacist can identify active ingredients and check whether two products duplicate each other.
Next-day impairment can be present without obvious sleepiness
A person may feel awake the morning after an insomnia medicine yet still have reduced alertness, reaction time, coordination, or driving ability. FDA notes that this possibility applies across insomnia medicines, although the likelihood and duration depend on the drug and formulation. Extended-release zolpidem has a particular next-morning impairment warning 1.
Risk can increase when a medicine lasts longer than expected in the body, the available sleep period is shortened, or another sedating substance is present. Age, liver function, other medications, and individual metabolism may also change exposure. These factors are reasons for a medication-specific review, not grounds for applying a universal cutoff or timing rule.
Do not drive, cycle in traffic, operate machinery, work at height, or perform another safety-critical task when you are sleepy, dizzy, unsteady, mentally slowed, or unable to focus. Persistent morning grogginess, balance problems, confusion, or memory gaps deserve a prompt medication review.
Complex sleep behavior is a specific safety problem
Complex sleep behavior means doing something while not fully awake and later having little or no memory of it. Reported behaviors include walking, cooking, eating, driving, having sex, or going outside.
FDA requires a boxed warning for eszopiclone, zaleplon, and zolpidem because rare episodes have led to falls, burns, poisoning, vehicle crashes, drowning, exposure to extreme cold, serious injury, and death. An episode can occur after the first use or after later use, with or without alcohol or another sedating drug. FDA considers a prior complex sleep behavior with one of these medicines a contraindication to further use 7.
Other prescription insomnia labels, including representative labels for daridorexant, ramelteon, and low-dose doxepin, also describe complex or abnormal sleep-related behavior 289. This does not mean the frequency or evidence is identical across drug classes.
If a possible episode occurs, secure immediate safety and contact the prescriber or an urgent clinical service before the next scheduled use. Emergency care is appropriate when the person is injured, missing, difficult to wake, breathing abnormally, or at risk of harming themselves or someone else.
Falls, memory, and cognition
Sedation, slower reactions, poor balance, low blood pressure, and confusion can contribute to falls. The concern is particularly important for older adults, people who already have balance problems, and anyone taking several medicines that affect the brain or blood pressure.
The 2023 American Geriatrics Society Beers Criteria identifies benzodiazepines as increasing the risk of cognitive impairment, delirium, falls, fractures, and motor-vehicle crashes in older adults. It describes Z-drugs as having similar adverse events in this age group, often with only modest improvement in sleep. It also flags first-generation antihistamines because of their strong anticholinergic effects and risk of confusion, dry mouth, constipation, falls, and delirium 6.
The Beers Criteria applies to most adults age 65 and older and supports clinical decision-making; it is not a universal list of medicines that no older person can ever use. The benefit, indication, alternatives, dose, and individual risk still matter.
Observational research has associated cumulative exposure to strong anticholinergic medicines with dementia. That association does not prove that a sleep aid caused the disease. Health conditions, early symptoms of neurodegenerative disease, medication combinations, and other differences between people can distort an observed relationship. Acute effects such as amnesia, confusion, or delirium are better-established concerns for particular sedating or anticholinergic drugs 6.
A new fall, marked unsteadiness, sudden confusion, or a significant memory gap warrants prompt clinical review. Sudden one-sided weakness, facial droop, trouble speaking, severe new headache, or loss of consciousness is an emergency rather than an assumed medication side effect.
Breathing risks and interactions depend on the exact drug
The most dangerous interactions often involve several substances that slow the central nervous system. FDA warns that combining an opioid with a benzodiazepine can cause profound sleepiness, slowed or difficult breathing, coma, and death. Alcohol and other central nervous system depressants can add to the risk 54.
Additive impairment is not limited to benzodiazepines. Labels for Z-drugs, dual orexin receptor antagonists, ramelteon, doxepin, and sedating antihistamines contain medication-specific cautions about alcohol, other sedating drugs, or impaired alertness 12893.
Risk assessment is especially important for someone with obstructive sleep apnea, chronic obstructive pulmonary disease, neuromuscular weakness, or another condition that affects breathing. The relevant evidence and label wording differ by medicine, so it is inaccurate to say every sleep product suppresses breathing to the same degree 293.
The same caution applies to food and drug interactions. Grapefruit affects some medicines but is not a universal sleep-medication interaction. Use the exact prescription label and a pharmacist's interaction check rather than avoiding or substituting a food based on a general list.
Check active ingredients before combining a sleep aid with a nighttime cold, allergy, headache, or pain product. The current U.S. diphenhydramine sleep-aid label warns against taking it with another product that contains diphenhydramine, including one used on the skin, and cautions about alcohol and other drugs that cause drowsiness 3.
Tolerance, dependence, addiction, and withdrawal are not synonyms
These terms describe different problems:
- Tolerance means the same amount has less effect after repeated exposure. First-generation antihistamines can lose sedating effect with continued use, and tolerance can occur with some prescription sedatives 613.
- Physical dependence means the body has adapted to a drug and may produce symptoms when exposure falls. It can happen during appropriate medical use and does not by itself mean addiction 4.
- Addiction or a substance use disorder involves impaired control, compulsive use, or continued use despite harm. It is not diagnosed solely because physical dependence is present 413.
- Rebound insomnia is a temporary worsening of sleep after reducing or discontinuing certain medicines. It is one possible withdrawal effect, not proof that the original insomnia has permanently worsened 13.
FDA requires every benzodiazepine to carry boxed warnings about misuse, addiction, physical dependence, and withdrawal. Physical dependence may develop after days to weeks of steady use, even when the medicine is taken as prescribed. Abrupt discontinuation or a rapid reduction can cause severe withdrawal, including seizures, and the safest plan must be individualized 4.
Eszopiclone, zaleplon, and zolpidem are Schedule IV controlled substances, and their labels may describe physical dependence, withdrawal, or rebound symptoms. They should not automatically be assigned the same risk magnitude or withdrawal pattern as benzodiazepines 13. Dual orexin receptor antagonists are also controlled substances, yet their labels and clinical profiles are different 2. Ramelteon, low-dose doxepin, antihistamines, melatonin, and individual supplements each require their own assessment.
Do not increase, combine, reduce, or discontinue a sleep medicine based on a generic article. A prescriber-led plan should account for the exact drug, formulation, duration of use, other substances, medical history, and previous withdrawal symptoms. A pharmacist can also identify interactions and duplicate ingredients.
Dietary supplements need ingredient-specific scrutiny
In the United States, melatonin is sold as a dietary supplement and is regulated differently from a prescription or over-the-counter drug. Analyses of marketed products have found that the melatonin content may differ substantially from the label, and some tested products have contained serotonin. Reported short-term effects in adults are generally mild and include headache, dizziness, nausea, and sleepiness, but long-term safety remains uncertain 11.
“Natural” does not establish effectiveness, purity, or safety. Valerian has inconsistent evidence for insomnia and uncertain long-term safety. Kava has been linked to rare but serious liver injury. L-tryptophan and 5-HTP can interact with medicines that affect serotonin. Each ingredient needs its own evidence and interaction check 12.
Pregnancy, breastfeeding, epilepsy, anticoagulant use, liver disease, and treatment involving several medicines are reasons to discuss a supplement with a clinician or pharmacist. Keep melatonin and every other sleep product out of children's reach; accidental melatonin ingestions in children have risen sharply 11.
Where medication fits in chronic insomnia care
Side effects are only one part of the decision. The relevant question is whether a particular medicine's expected benefit outweighs its risks for a particular person and goal.
Cognitive behavioral therapy for insomnia, or CBT-I, is recommended as the initial treatment for chronic insomnia. It is a structured treatment that addresses the behaviors, timing, and thought patterns that maintain insomnia. The American College of Physicians recommends shared decision-making about short-term medication when CBT-I alone has not been enough 14.
Current VA/DoD guidance also prioritizes CBT-I. When medication is considered, it distinguishes among individual agents rather than endorsing “sleeping pills” as one category. Its suggested options include doxepin, eszopiclone, lemborexant, suvorexant, zaleplon, and zolpidem, while it suggests against benzodiazepines, diphenhydramine, trazodone, and antipsychotics for chronic insomnia. These are guideline recommendations with varying evidence strength, not instructions to switch or stop a medicine without an individualized review 10.
A sleep medicine can also be prescribed for a reason other than chronic insomnia. Narcolepsy symptoms, a circadian-rhythm disorder, a coexisting mental-health condition, and short-term situational insomnia do not have identical treatment decisions. The diagnosis and purpose should be clear before benefits and harms are weighed.
How to prepare for a medication review
Bring the actual containers, photos of their labels, or a complete written list. Include prescriptions, over-the-counter products, supplements, cannabis, alcohol, and other substances. Useful questions include:
- What is the generic name, formulation, and reason for this medicine?
- What benefit should it provide, and how will we judge whether it is helping?
- Which next-day effects or unusual nighttime behaviors matter most for this drug?
- Does it duplicate an ingredient in a cold, allergy, pain, or nighttime product?
- How does it interact with my other medicines, alcohol, cannabis, or supplements?
- Do sleep apnea, lung disease, liver or kidney disease, pregnancy, falls, or mood symptoms change the risk?
- If a change becomes appropriate, how will it be supervised and what symptoms need urgent care?
Mention any reduced effect, desire to take more, early refill, use for reasons other than sleep, or fear of missing a dose. These details help distinguish ongoing insomnia from tolerance, physical dependence, or a developing use problem without assuming that one necessarily means another.
When to get help
Seek emergency care now for:
- slow, shallow, difficult, or stopped breathing
- blue or gray lips or skin
- inability to wake, collapse, coma, or a seizure
- swelling of the lips, tongue, face, or throat, especially with breathing or swallowing difficulty
- a suspected overdose or dangerous medication combination
- a major injury or immediate danger during unusual nighttime behavior
- an immediate risk of suicide or harm to another person
Contact the prescriber or an urgent clinical service before the next scheduled use after a complex sleep behavior or unexplained nighttime activity with amnesia. Also seek prompt advice for severe next-day impairment, a fall, new confusion or hallucinations, worsening breathing, a major mood or behavior change, suicidal thoughts, or a newly discovered pregnancy.
Arrange a routine medication review for persistent grogginess, dizziness, balance trouble, dry mouth, constipation, difficulty urinating, reduced benefit, return of insomnia, concern about reliance, or any new prescription, over-the-counter product, or supplement.
The bottom line
The safest way to understand a sleep medication is to identify its exact active ingredient and evaluate the risks that belong to that drug. Next-day impairment is possible across several groups, but complex sleep behaviors, anticholinergic effects, respiratory interactions, physical dependence, and withdrawal do not occur with equal likelihood or severity across all products.
A clear medication list, an ingredient check, and a prescriber or pharmacist review are more useful than a generic list of “sleeping pill” side effects. Medication changes should be individualized, and urgent symptoms should be treated according to their severity rather than assumed to be a normal part of treatment.
